Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks memory loss in kids after brain radiation

NCT ID NCT06599879

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how radiation to the brain affects memory in children who had a brain tumor. Researchers will test memory and thinking skills in 130 children ages 4 to 12, starting 2 years after radiation and again 2 years later. The goal is to learn which parts of the brain are most affected, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 14 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient who has received localised brain irradiation or craniospinal irradiation for a brain tumour whose treatment includes first-line radiotherapy. 2. Patient with one of the following tumour types: ependymomas, medulloblastomas, malignant germ cell tumours, craniopharyngioma, pinealoblastoma. 3. Patient aged between 4 and 12 years at the time of radiotherapy treatment. 4. End of irradiation within 2 years (+/-3 months) prior to inclusion. 5. Patient having been treated by photontherapy or proton therapy. 6. Sufficient visual, auditory (with authorised hearing aid) and oral or written expression capacity to carry out the neuropsychological tests properly. 7. Proficiency in the French language by the patient and parent(s). 8. Patient affiliated to a Social Security scheme in France. 9. Informed consent signed by the patient/legal parent(s)/guardian(s) in accordance with French law and Good Clinical Practice. Exclusion Criteria: 1. Patient presenting with severe ataxia. 2. Patient with a recurrence of the disease. 3. Not applicable since protocol version 2. Metastatic patient. 4. Any contraindication to MRI for patients included in Toulouse (i.e. in particular patients with a pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, patients with haemostatic clips on intracerebral aneurysms, patients with orthopaedic implants, claustrophobic patients). 5. Patients undergoing psychostimulant or psychotropic treatment (in particular methylphenidate, antidepressants). 6. Any psychological, family, geographical or sociological condition that prevents compliance with medical monitoring and/or the procedures set out in the study protocol. 7. Patients deprived of their liberty or under legal protection. 8. Severe posterior fossa syndrome with akinetic mutism.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm craniopharyngioma ependymoma malignant germ cell tumor medulloblastoma pineoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain tumor, pediatric

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHM - Hôpital la Timone

    NOT_YET_RECRUITING

    Marseille, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, France

  • Centre Eugène Marquis

    NOT_YET_RECRUITING

    Rennes, France

  • Centre François Baclesse

    RECRUITING

    Caen, France

  • Centre Georges François Leclerc

    NOT_YET_RECRUITING

    Dijon, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, France

  • Centre Oscar Lambret

    NOT_YET_RECRUITING

    Lille, France

  • Centre Paul Strauss

    RECRUITING

    Strasbourg, France

  • IUCT-O

    RECRUITING

    Toulouse, France

  • Institut Curie

    NOT_YET_RECRUITING

    Paris, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

  • Institut de Cancérologie de Lorraine

    RECRUITING

    Vandœuvre-lès-Nancy, France

  • Institut de Cancérologie de l'Ouest

    NOT_YET_RECRUITING

    Saint-Herblain, France

  • Institut du Cancer de Montpellier

    NOT_YET_RECRUITING

    Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.